[go: up one dir, main page]

DE69328910D1 - Verwendung von 9-cis-Retinsäure sowie ihre Salze und Ester, zur Behandlung von Epitheltumore - Google Patents

Verwendung von 9-cis-Retinsäure sowie ihre Salze und Ester, zur Behandlung von Epitheltumore

Info

Publication number
DE69328910D1
DE69328910D1 DE69328910T DE69328910T DE69328910D1 DE 69328910 D1 DE69328910 D1 DE 69328910D1 DE 69328910 T DE69328910 T DE 69328910T DE 69328910 T DE69328910 T DE 69328910T DE 69328910 D1 DE69328910 D1 DE 69328910D1
Authority
DE
Germany
Prior art keywords
esters
salts
treatment
retinoic acid
cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69328910T
Other languages
English (en)
Other versions
DE69328910T2 (de
Inventor
Werner Bollag
Joseph Francis Grippo
Arthur Levin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Basilea Pharmaceutica AG
Original Assignee
HOFFMANN LA ROCHE
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HOFFMANN LA ROCHE, F Hoffmann La Roche AG filed Critical HOFFMANN LA ROCHE
Publication of DE69328910D1 publication Critical patent/DE69328910D1/de
Application granted granted Critical
Publication of DE69328910T2 publication Critical patent/DE69328910T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Saccharide Compounds (AREA)
DE69328910T 1992-01-22 1993-01-11 Verwendung von 9-cis-Retinsäure sowie ihre Salze und Ester, zur Behandlung von Epitheltumore Expired - Lifetime DE69328910T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82378692A 1992-01-22 1992-01-22
US82392892A 1992-01-22 1992-01-22
US82374192A 1992-01-22 1992-01-22
US82464792A 1992-01-23 1992-01-23

Publications (2)

Publication Number Publication Date
DE69328910D1 true DE69328910D1 (de) 2000-08-03
DE69328910T2 DE69328910T2 (de) 2001-01-11

Family

ID=27505866

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69328910T Expired - Lifetime DE69328910T2 (de) 1992-01-22 1993-01-11 Verwendung von 9-cis-Retinsäure sowie ihre Salze und Ester, zur Behandlung von Epitheltumore

Country Status (20)

Country Link
EP (1) EP0552624B1 (de)
JP (1) JP3631259B2 (de)
CN (2) CN1068200C (de)
AT (1) ATE194077T1 (de)
AU (1) AU667864B2 (de)
CA (1) CA2087251C (de)
CY (1) CY2251B1 (de)
CZ (1) CZ282548B6 (de)
DE (1) DE69328910T2 (de)
DK (1) DK0552624T3 (de)
ES (1) ES2148184T3 (de)
GR (1) GR3034323T3 (de)
HU (2) HU212734B (de)
IL (1) IL104450A (de)
NO (1) NO302274B1 (de)
NZ (1) NZ245686A (de)
PH (1) PH31621A (de)
PT (1) PT552624E (de)
RU (1) RU2119333C1 (de)
TW (1) TW226329B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2123223C (en) 1991-12-18 2001-10-09 Ronald M. Evans Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US7056954B2 (en) 1991-12-18 2006-06-06 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US5968989A (en) 1991-12-18 1999-10-19 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5962731A (en) * 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5549888A (en) * 1994-01-31 1996-08-27 Procter & Gamble Aqueous topical anti-acne compositions of low pH
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
CA2218685A1 (en) * 1995-04-21 1996-10-24 Ligand Pharmaceuticals Incorporated Inhibition of apoptosis in cells expressing fas-ligand following activation
DE19523079A1 (de) * 1995-06-26 1997-01-02 Basf Ag Ester und Amide der 9(Z)-Retinsäure
AU7074496A (en) * 1995-09-18 1997-04-09 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
EP1426048A3 (de) * 1995-09-18 2004-06-16 Ligand Pharmaceuticals, Inc. Behandlung der Hypertriglyceridämie mit RXR Agonisten in Kombination mit einem PPARgamma Agonist
TW442459B (en) * 1996-04-15 2001-06-23 Hoffmann La Roche Retinoid compounds, pharmaceutical composition comprising same and process for the preparation thereof
FR2765480B1 (fr) 1997-07-07 1999-09-10 Oreal Utilisation pour le revetement des matieres keratiniques d'un materiau polymerique hybride ; compositions cosmetiques ou dermatologiques
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
AU1707599A (en) * 1998-03-20 1999-10-18 Warner-Lambert Company Retinoid-glitazone combinations
KR100588284B1 (ko) 1999-04-07 2006-06-09 상꾜 가부시키가이샤 아민 유도체 화합물
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
AU2003223477A1 (en) * 2002-04-05 2003-10-27 University Of Utah Research Foundation Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2
AU2003270414A1 (en) * 2002-09-06 2004-03-29 Oregon Health And Science University Effect of vitamin a gel on paranasal sinus mucosal regeneration
EP1527774A1 (de) * 2003-11-03 2005-05-04 Basilea Pharmaceutica AG Neue Zubereitungsform für retinoidhaltige Weichgelatinekapseln
JP4825957B2 (ja) * 2005-03-29 2011-11-30 国立大学法人 鹿児島大学 抗腫瘍剤
KR101710505B1 (ko) 2009-09-15 2017-02-27 노벨리언 테라퓨틱스 인코포레이티드 리피드 비히클에 9-시스-레티닐 에스테르를 포함하는 약제 처방
WO2011129765A1 (en) * 2010-04-16 2011-10-20 Davos Life Science Pte. Ltd. Synergistic interaction of at least one vitamin e component and tyrosinase inhibitors for dermatological applications
CN102939081A (zh) 2010-04-19 2013-02-20 Qlt股份有限公司 用于治疗或改善与内源性类视黄醇缺乏有关的视觉障碍的治疗方案和方法
EP2819667B8 (de) 2012-03-01 2020-03-04 Retinagenix Therapeutics, Inc. Retinalderivate zur verbesserung der visuellen funktion
JP6182728B2 (ja) * 2012-11-02 2017-08-23 国立大学法人名古屋大学 幹細胞を標的とした薬効及び毒性の評価法
WO2022051831A1 (pt) 2020-09-11 2022-03-17 Chemyunion Ltda. Composição, uso de composição, método cosmético e método para modular a produção de sebo
EP4489744A1 (de) * 2022-03-08 2025-01-15 Mastery Biotech Co., Ltd. Pharmazeutische zusammensetzung mit retinoinsäure und kohlenhydrat und verwendung davon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA713539B (en) * 1970-06-23 1972-02-23 Hoffmann La Roche Pharmaceutical compositions
WO1988007857A1 (en) * 1987-04-06 1988-10-20 Daltex Medical Sciences, Inc. Treatment of aged skin with oral 13-cis-retinoic acid
US4994491A (en) * 1988-12-14 1991-02-19 Molecular Design International Dermal uses of trans-retinoids for the treatment of cancer
LU86969A1 (fr) * 1987-08-12 1989-03-08 Oreal Association de derives de pyrimidine et de retinoides en composants separes pour induire et stimuler la croissance des cheveux et diminuer leur chute
CA2123223C (en) * 1991-12-18 2001-10-09 Ronald M. Evans Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor

Also Published As

Publication number Publication date
NO302274B1 (no) 1998-02-16
HU211167A9 (en) 1995-11-28
ES2148184T3 (es) 2000-10-16
NZ245686A (en) 1995-05-26
EP0552624B1 (de) 2000-06-28
AU667864B2 (en) 1996-04-18
IL104450A0 (en) 1993-05-13
DE69328910T2 (de) 2001-01-11
NO930206L (no) 1993-07-23
CN1256916A (zh) 2000-06-21
CA2087251C (en) 2003-06-24
CN1074826A (zh) 1993-08-04
JPH06107542A (ja) 1994-04-19
HUT63053A (en) 1993-07-28
ATE194077T1 (de) 2000-07-15
CN1155376C (zh) 2004-06-30
IL104450A (en) 1997-03-18
CZ372892A3 (en) 1993-12-15
PH31621A (en) 1999-01-12
RU2119333C1 (ru) 1998-09-27
CN1068200C (zh) 2001-07-11
CY2251B1 (en) 2003-07-04
HU9300116D0 (en) 1993-04-28
HU212734B (en) 1996-10-28
EP0552624A1 (de) 1993-07-28
NO930206D0 (no) 1993-01-21
AU3186193A (en) 1993-07-29
TW226329B (de) 1994-07-11
GR3034323T3 (en) 2000-12-29
JP3631259B2 (ja) 2005-03-23
CZ282548B6 (cs) 1997-08-13
CA2087251A1 (en) 1993-07-23
PT552624E (pt) 2000-10-31
DK0552624T3 (da) 2000-09-25

Similar Documents

Publication Publication Date Title
DE69328910D1 (de) Verwendung von 9-cis-Retinsäure sowie ihre Salze und Ester, zur Behandlung von Epitheltumore
DE3850109D1 (de) 13-trans-retinsäureester.
RU93005355A (ru) Фармакологические композиции
DE3881299D1 (de) Retinoide zur behandlung lichtgeschaedigter haut.
DE69526183D1 (de) 3-benzoylphenylessigsäure-derivate enthaltende topische zusammensetzungen zur behandlung der ophthalmischen entzündungserkrankungen
DE69526103D1 (de) Dermatologische zusammensetzungen, welche benzylneroxid und ein mittel zur verminderung von hautreizungen enthalten
FR2562539B1 (fr) Nouveaux derives de l'acide vinyl-4 benzoique, leur procede de preparation et leurs applications en therapeutique et comme ligands
DE602004016847D1 (de) Topische verwendung von valproinsäure zur behandlung von psoriasis und akne
ATE220536T1 (de) Kosmetische und/oder dermatologische zusammensetzung enthaltend salicylsäure oder ihre derivate und ihre verwendung
ATE145136T1 (de) Verwendung von ketoconazol und ein retinoid zur behandlung der akne vulgaris
DE69315927D1 (de) Kosmetische Zusammensetzung, die einen Lipidstoff und eine Hydroxy - oder Ketofettsäure enthält
KR930016100A (ko) 약제학적 조성물
ATE311871T1 (de) Verwendung von zinksalzen der konjugierten linoleinsäuren zur behandlung von hautkrankheiten
NO20002649L (no) Anvendelse av en blanding av diol og en alfa-hydroksysyre for behandling av hyperkeratotiske hudsykdommer
DE68919009D1 (de) Verwendung von 5-Amino-salicylsäure für die Behandlung von Hautkrankheiten.
EP0262334A3 (de) Entzündungshemmende Mittel
ATE133157T1 (de) Arylalkylester der 4,5-dihydoxy-9,10-dihydro-9,10-dioxo-2-anthrace carbonsäure und deren therapeutische verwendung
AU6608994A (en) Compositions for the treatment of inflammatory proliferative skin disease and their use
ATE86611T1 (de) Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.
EP0744175A3 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an alpha-Hydroxyfettsäuren
ATE234613T1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE3786705D1 (de) Verwendung eines ornithin-decarboxylate-inhibitors zur herstellung eines praeparats fuer die behandlung, zusammen mit lak-zellen und interleukin-2, von tumoren.
Kligman et al. Lifetime topical application of tretinoin to hairless mice.
FI910308A0 (fi) Vattenloesliga vitamin a preparationer foer applicering pao huden.
DE59813022D1 (de) Verwendung von estern der cis-6-hexadecensäure zur behandlung von psoriasis, allergien und autoimmunerkrankungen sowie bei trockener und empfindlicher haut

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BASILEA PHARMACEUTICA AG, BINNINGEN, CH